Sihuan Pharmaceutical Holdings Group (HKG:0460) said its non-wholly owned subsidiary Xuanzhu Biopharmaceutical (HKG:2575) is due for inclusion to the Hang Seng Composite Index on March 9, according to a Hong Kong bourse filing Friday.
Xuanzhu Biopharmaceutical went public in Hong Kong in October of last year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.